Arthur J. Gallagher & Co.
AJG
$0.00
+5.33%
Arthur J. Gallagher & Co. is a global insurance brokerage and risk management services firm, primarily serving middle-market companies through its core insurance brokerage business and third-party claims adjustment services. The company is a major player in the insurance brokerage industry, distinguished by its significant international footprint, with about a third of its revenue generated outside the United States. The current investor narrative is heavily influenced by the stock's significant underperformance relative to the broader market over the past year, as evidenced by a -48.15% relative strength figure, which has likely sparked debates around valuation, the impact of a potential hard insurance market cycle, and the company's ability to execute its growth strategy amidst macroeconomic headwinds.…
AJG
Arthur J. Gallagher & Co.
$0.00
AJG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arthur J. Gallagher & Co.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
7 analysts
Implied Upside
—
vs. current price
Analyst Count
7
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage is limited, with only 7 analysts providing estimates, which suggests this large-cap stock may have less institutional scrutiny than peers, potentially leading to higher volatility and less efficient price discovery. The consensus sentiment, inferred from recent institutional actions, appears mixed but with a bullish tilt, as evidenced by upgrades from firms like Barclays (to Overweight from Underweight) and Mizuho (to Outperform from Neutral) in Q1 2026, though several firms maintain Hold or Neutral ratings. The target price range is implied through earnings estimates, with a low EPS of $15.38 and a high of $18.05; applying a forward PE multiple near the current 15.20x would imply a target price range roughly between $234 and $274, suggesting potential upside from the current $226.01 price, with the high end of the range likely assuming successful execution on growth initiatives and multiple expansion.
Bulls vs Bears: AJG Investment Factors
The investment debate for AJG centers on a clash between strong top-line growth and a deteriorating profitability profile. The bull case is anchored in robust 33.58% YoY revenue growth, a reasonable forward P/E of 15.20x, strong free cash flow, and a recent technical rebound from deeply oversold levels. The bear case highlights severe margin compression, a 29% annual price decline, volatile earnings, and a high trailing P/E that signals depressed profits. Currently, the bearish evidence appears stronger, as the stock's significant underperformance and collapsing margins are concrete, present-tense negatives, while the bull case relies heavily on a forecasted earnings recovery. The single most important tension is whether the company's impressive revenue growth can translate into stable, expanding profitability, or if margin pressure is a structural issue that will keep earnings depressed and validate the high trailing P/E as a warning sign.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 33.58% YoY to $3.628B, significantly outpacing sector averages and demonstrating robust top-line momentum despite market headwinds. This growth is supported by a solid international footprint, with about one-third of revenue generated outside the U.S.
- Attractive Forward Valuation: The stock trades at a forward P/E of 15.20x, which is reasonable for a market leader and implies significant earnings recovery is priced in. This is a steep discount to the trailing P/E of 44.39x, suggesting the market expects strong profit normalization.
- Robust Free Cash Flow: The company generated $1.785B in trailing-twelve-month free cash flow, providing ample internal resources to fund its active acquisition strategy and shareholder returns. A manageable debt-to-equity ratio of 0.60 and a current ratio of 1.06 indicate a solid financial foundation.
- Positive Analyst Upgrades: Recent institutional sentiment has turned bullish, with Barclays upgrading to Overweight and Mizuho to Outperform in Q1 2026. Analyst EPS estimates imply a target price range of approximately $234 to $274, offering 3.5% to 21% upside from the current price of $226.01.
Bearish
- Severe Profitability Compression: Gross margin collapsed to 39.11% in Q4 2025 from 48.04% in Q1 2025, indicating significant pressure on earnings quality. This compression, alongside a trailing P/E of 44.39x, reflects depressed earnings and raises questions about the sustainability of the business model's profitability.
- Deep Underperformance & Downtrend: The stock is down 29.01% over the past year, underperforming the S&P 500 by 48.15%, and remains 30.1% below its 52-week high. Despite a recent bounce, the 3-month performance of 9.13% still lags the SPY's 14.97% gain, confirming the longer-term bearish trend.
- Volatile and Declining Earnings: Q4 2025 net income of $151M is a sharp sequential decline from $272.7M in Q3 and $704.4M in Q1, indicating severe quarterly earnings volatility. This lumpiness, likely tied to acquisition timing and contingent revenue, makes forecasting difficult and increases investor uncertainty.
- Limited Analyst Coverage: Only 7 analysts cover this $67.4B market cap stock, suggesting less institutional scrutiny and potentially less efficient price discovery. This can lead to higher volatility and mispricing, as seen in the stock's 44.95% maximum drawdown over the past year.
AJG Technical Analysis
The stock is in a pronounced downtrend, having declined 29.01% over the past year, which starkly contrasts with the S&P 500's 19.14% gain. Currently trading at $226.01, the price sits just 18.7% above its 52-week low of $190.75 and 30.1% below its 52-week high of $323.25, positioning it in the lower quartile of its annual range and suggesting it is in a deep value or oversold territory, though it remains vulnerable to further declines. Recent momentum shows a significant divergence, with the stock posting a strong 11.42% gain over the past month against a -2.86% move for the SPY, indicating a potential short-term rebound or oversold bounce; however, this positive 1-month move is overshadowed by a still-negative 3-month performance of 9.13%, which lags the SPY's 14.97% gain, signaling that the longer-term bearish trend remains intact despite recent strength. Key technical levels are clearly defined, with immediate support at the 52-week low of $190.75 and major resistance at the 52-week high of $323.25; a sustained breakout above the recent recovery highs near $230 would be needed to signal a trend reversal, while a breakdown below $190.75 could trigger another leg down. The stock's beta of 0.53 indicates it has been significantly less volatile than the market during this downturn, which is atypical for a stock in a steep decline and may suggest it is being viewed as a relative safe haven within its sector.
Beta
0.51
0.51x market volatility
Max Drawdown
-45.0%
Largest decline past year
52-Week Range
$191-$318
Price range past year
Annual Return
-20.0%
Cumulative gain past year
| Period | AJG Return | S&P 500 |
|---|---|---|
| 1m | +22.7% | -1.3% |
| 3m | +16.0% | +13.6% |
| 6m | -1.4% | +9.0% |
| 1y | -20.0% | +19.1% |
| ytd | -1.4% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AJG Fundamental Analysis
Revenue growth has been robust but volatile on a quarterly basis, with Q4 2025 revenue of $3.628 billion representing a substantial 33.58% year-over-year increase; however, this follows a sequential decline from Q1 2025's $3.727 billion, indicating potential lumpiness in growth, likely driven by the timing of acquisitions and contingent revenue. The company is profitable, with Q4 2025 net income of $151 million and a gross margin of 39.11%, but profitability has compressed significantly from the stronger margins seen in earlier quarters of 2025, such as the 48.04% gross margin in Q1, suggesting recent quarters have faced pressure on earnings quality or mix. The balance sheet and cash flow position remains solid, with a manageable debt-to-equity ratio of 0.60, a current ratio of 1.06 indicating sufficient short-term liquidity, and strong trailing twelve-month free cash flow of $1.785 billion, which provides ample internal resources to fund the company's active acquisition strategy and shareholder returns without over-reliance on external financing.
Quarterly Revenue
$3.6B
2025-12
Revenue YoY Growth
+0.33%
YoY Comparison
Gross Margin
+0.39%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AJG Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 44.39x, while the forward PE is a much lower 15.20x; this wide gap implies the market expects a significant recovery in earnings over the next twelve months, likely pricing in the cyclical rebound of the insurance brokerage sector and margin normalization. Compared to sector averages, the stock's trailing PE of 44.39x and Price-to-Sales (PS) ratio of 4.83x are not directly comparable without provided industry benchmarks, but the forward PE of 15.20x appears reasonable for a market leader if growth expectations are met, though the current premium on trailing earnings reflects depressed recent profitability. Historically, the current trailing PE of 44.39x is near the higher end of its own range over the past several quarters, which have seen values fluctuate from the low 20s to over 110x; this high multiple relative to its own history suggests the market is currently valuing the stock based on depressed earnings (making the PE appear high) rather than peak earnings, indicating expectations for a sharp earnings recovery are already embedded in the price.
PE
44.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -378x~112x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AJG faces significant profitability risk, with gross margins compressing from 48.04% in Q1 2025 to 39.11% in Q4 2025, a decline of nearly 900 basis points. This earnings volatility, evidenced by net income dropping from $704M to $151M over the same period, raises questions about the quality and sustainability of its growth, which is partly driven by an acquisition-heavy strategy. While free cash flow of $1.785B is strong, the company's reliance on acquisitions for growth carries integration and execution risks that could further pressure margins if not managed perfectly.
Market & Competitive Risks: The stock's valuation presents a key market risk. Its trailing P/E of 44.39x is historically high for the company, making it vulnerable to multiple compression if the anticipated earnings rebound falters. With a beta of 0.53, AJG has demonstrated lower volatility than the market during its downturn, but this relative stability could be tested if sector-wide headwinds in insurance brokerage (e.g., a softening insurance market cycle) intensify. The stock's -48.15% relative strength over the past year shows it is already deeply out of favor, leaving it susceptible to further selling if macro conditions worsen or if growth decelerates.
Worst-Case Scenario: The worst-case scenario involves a failure to arrest the margin decline, leading to consecutive earnings misses that shatter the forward earnings recovery narrative. This could trigger a wave of analyst downgrades, a re-rating to a lower multiple, and a flight of remaining investor capital. In this adverse scenario, the stock could retest and break below its 52-week low of $190.75, representing a potential downside of -15.6% from the current price of $226.01. A more severe bear case, factoring in a historical max drawdown of -44.95%, suggests a theoretical downside to approximately $124, though a retest of the $190 support level is a more immediate and realistic risk.